Pulmonx annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
Pulmonx Stock-Based Compensation Growth & History (LUNG)
Pulmonx's stock-based compensation was $21.2M for fiscal 2025.
View full Pulmonx company overviewPulmonx annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $21.2M | −$1.7M | −7.50% |
| 2024 | 2024-12-31 | $23.0M | $854,000 | +3.86% |
| 2023 | 2023-12-31 | $22.1M | $5.7M | +34.39% |
| 2022 | 2022-12-31 | $16.4M | $5.9M | +56.17% |
| 2021 | 2021-12-31 | $10.5M | $7.3M | +229.37% |
| 2020 | 2020-12-31 | $3.2M | $2.8M | +778.30% |
| 2019 | 2019-12-31 | $364,000 | −$2,000 | −0.55% |
| 2018 | 2018-12-31 | $366,000 | — | — |
Pulmonx quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.7M | −$2.5M | −40.49% |
| Q1 2026 | 2026-03-31 | $4.1M | −$1.5M | −26.30% |
| Q4 2025 | 2025-12-31 | $4.2M | −$1.3M | −23.21% |
| Q3 2025 | 2025-09-30 | $5.2M | −$673,000 | −11.53% |
| Q2 2025 | 2025-06-30 | $6.2M | $294,000 | +4.97% |
| Q1 2025 | 2025-03-31 | $5.6M | −$61,000 | −1.08% |
| Q4 2024 | 2024-12-31 | $5.5M | −$75,000 | −1.34% |
| Q3 2024 | 2024-09-30 | $5.8M | −$164,000 | −2.73% |
| Q2 2024 | 2024-06-30 | $5.9M | $58,000 | +0.99% |
| Q1 2024 | 2024-03-31 | $5.7M | $1.0M | +22.32% |
| Q4 2023 | 2023-12-31 | $5.6M | $1.4M | +31.81% |
| Q3 2023 | 2023-09-30 | $6.0M | $1.7M | +39.54% |
| Q2 2023 | 2023-06-30 | $5.9M | $1.5M | +33.74% |
| Q1 2023 | 2023-03-31 | $4.6M | $1.1M | +32.02% |
| Q4 2022 | 2022-12-31 | $4.2M | $1.2M | +41.00% |
| Q3 2022 | 2022-09-30 | $4.3M | $1.4M | +46.43% |
| Q2 2022 | 2022-06-30 | $4.4M | $2.1M | +89.58% |
| Q1 2022 | 2022-03-31 | $3.5M | $1.2M | +54.89% |
| Q4 2021 | 2021-12-31 | $3.0M | $701,000 | +30.33% |
| Q3 2021 | 2021-09-30 | $2.9M | $2.4M | +467.18% |
| Q2 2021 | 2021-06-30 | $2.3M | $2.2M | +1354.09% |
| Q1 2021 | 2021-03-31 | $2.3M | $2.1M | +985.17% |
| Q4 2020 | 2020-12-31 | $2.3M | — | — |
| Q3 2020 | 2020-09-30 | $518,000 | $446,000 | +619.44% |
| Q2 2020 | 2020-06-30 | $159,000 | — | — |
| Q1 2020 | 2020-03-31 | $209,000 | — | — |
| Q3 2019 | 2019-09-30 | $72,000 | — | — |
Pulmonx stock-based compensation trends
Over the last five fiscal years, Pulmonx's stock-based compensation increased from $3.2M to $21.2M, a change of $18.0M. The latest reported quarter, Q2 2026, shows $3.7M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pulmonx source filings ↗